GlassScriptPhysician profile
Joshua E Radecki
NPI 1215311972
$11,553.47
in general payments reported to CMS, 2019-2025
42 companies · $2,598 in 2025
The $2,598 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $2,255 · 2023: $2,530 · 2024: $2,995 · 2025: $2,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,448 · Education: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,448.09 |
| Education | $675.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,450.67 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,067.34 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $975.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $970.49 | 2021-2025 | |
| Boston Scientific Corporation | $767.12 | 2024-2025 | General - Brady, Watchman Flx |
| Novo Nordisk INC | $721.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $531.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $519.37 | 2021-2025 | |
| Astellas Pharma US INC | $422.52 | 2022-2025 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $411.22 | 2022-2025 | Descovy |
| Janssen Pharmaceuticals, INC | $372.39 | 2021-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $298.62 | 2022-2024 | |
| Amgen INC. | $296.95 | 2021-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $254.12 | 2022-2024 | |
| Dexcom, INC. | $233.91 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $206.87 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $203.54 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.90 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.18 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Mylan Specialty L.P. | $183.77 | 2021-2024 | Yupelri |
| Viatris Specialty LLC | $179.23 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $140.26 | 2022 | |
| Lundbeck LLC | $109.32 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $97.42 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $95.88 | 2021-2025 | Trintellix |
| Amneal Pharmaceuticals LLC | $90.19 | 2023-2024 | Unithroid |
| Merck Sharp & Dohme LLC | $83.43 | 2021-2025 | Gardasil 9, Gardasil, Capvaxive |
| Axsome Therapeutics, INC. | $66.89 | 2025 | Auvelity |
| Viiv Healthcare Company | $44.40 | 2024-2025 | Apretude |
| Optinose US, INC. | $44.39 | 2022 | |
| Amarin Pharma, INC. | $40.02 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.62 | 2024-2025 | Camzyos, Eliquis |
| Daiichi Sankyo INC. | $38.03 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $34.77 | 2021 | |
| Hologic Sales and Service, LLC | $24.11 | 2024 | Aptima |
| Exeltis, USA INC. | $23.73 | 2025 | Slynd |
| Verona Pharma, INC. | $23.03 | 2025 | Ohtuvayre |
| Insulet Corporation | $22.84 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $21.28 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $19.37 | 2022 | |
| Abbott Laboratories | $17.89 | 2022 | |
| Shield Therapeutics INC | $14.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Radecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.